Burghaus R - Search Results

1

Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions.

Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Thelen K, et al. Among authors: burghaus r. J Pharm Sci. 2011 Dec;100(12):5324-45. doi: 10.1002/jps.22726. Epub 2011 Oct 12. J Pharm Sci. 2011. PMID: 21993815

2

Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.

Willmann S, Becker C, Burghaus R, Coboeken K, Edginton A, Lippert J, Siegmund HU, Thelen K, Mück W. Willmann S, et al. Among authors: burghaus r. Clin Pharmacokinet. 2014 Jan;53(1):89-102. doi: 10.1007/s40262-013-0090-5. Clin Pharmacokinet. 2014. PMID: 23912563 Free PMC article. Clinical Trial.

3

Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data.

Nagamine T, Gillette B, Pakhomov A, Kahoun J, Mayer H, Burghaus R, Lippert J, Saxena M. Nagamine T, et al. Among authors: burghaus r. Sci Rep. 2020 Dec 7;10(1):21340. doi: 10.1038/s41598-020-77286-6. Sci Rep. 2020. PMID: 33288774 Free PMC article.

4

NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.

Schmitt W, Rühs H, Burghaus R, Diedrich C, Duwal S, Eissing T, Garmann D, Meyer M, Ploeger B, Lippert J. Schmitt W, et al. Among authors: burghaus r. Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. Clin Pharmacol Ther. 2021. PMID: 33630302 Free PMC article.

5

A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.

Frechen S, Solodenko J, Wendl T, Dallmann A, Ince I, Lehr T, Lippert J, Burghaus R. Frechen S, et al. Among authors: burghaus r. CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):633-644. doi: 10.1002/psp4.12636. Epub 2021 May 24. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33946131 Free PMC article.

6

Data-driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment.

Fendt R, Hofmann U, Schneider ARP, Schaeffeler E, Burghaus R, Yilmaz A, Blank LM, Kerb R, Lippert J, Schlender JF, Schwab M, Kuepfer L. Fendt R, et al. Among authors: burghaus r. CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):782-793. doi: 10.1002/psp4.12646. Epub 2021 Jun 26. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34053199 Free PMC article. Clinical Trial.

7

Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.

Chelliah V, Lazarou G, Bhatnagar S, Gibbs JP, Nijsen M, Ray A, Stoll B, Thompson RA, Gulati A, Soukharev S, Yamada A, Weddell J, Sayama H, Oishi M, Wittemer-Rump S, Patel C, Niederalt C, Burghaus R, Scheerans C, Lippert J, Kabilan S, Kareva I, Belousova N, Rolfe A, Zutshi A, Chenel M, Venezia F, Fouliard S, Oberwittler H, Scholer-Dahirel A, Lelievre H, Bottino D, Collins SC, Nguyen HQ, Wang H, Yoneyama T, Zhu AZX, van der Graaf PH, Kierzek AM. Chelliah V, et al. Among authors: burghaus r. Clin Pharmacol Ther. 2021 Mar;109(3):605-618. doi: 10.1002/cpt.1987. Epub 2020 Aug 14. Clin Pharmacol Ther. 2021. PMID: 32686076 Free PMC article. Review.

8

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.

Burghaus R, Coboeken K, Gaub T, Niederalt C, Sensse A, Siegmund HU, Weiss W, Mueck W, Tanigawa T, Lippert J. Burghaus R, et al. Front Physiol. 2014 Nov 7;5:417. doi: 10.3389/fphys.2014.00417. eCollection 2014. Front Physiol. 2014. PMID: 25426077 Free PMC article.

9

Modeling and Simulation of In Vivo Drug Effects.

Lippert J, Burghaus R, Kuepfer L, Ploeger B, Schaller S, Schmitt W, Willmann S. Lippert J, et al. Among authors: burghaus r. Handb Exp Pharmacol. 2016;232:313-29. doi: 10.1007/164_2015_21. Handb Exp Pharmacol. 2016. PMID: 26578524 Review.

10

Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

Willmann S, Zhang L, Mayer H, Siegmund HU, Tanigawa T, Kaneko M, Peters G, Weitz JI, Berkowitz SD, Burghaus R. Willmann S, et al. Among authors: burghaus r. Blood Adv. 2018 Nov 27;2(22):3193-3195. doi: 10.1182/bloodadvances.2018027078. Blood Adv. 2018. PMID: 30482761 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results